Can the agreement be signed electronically?

Yes. Electronic signatures satisfy ESIGN (15 U.S.C. ch. 96) and UETA where adopted when intent, consent, attribution, and record retention are demonstrated. Exceptions such as wills or certain court filings remain excluded; follow consumer-consent requirements for healthcare-related records.

What identification is required at collection?

Collect a government-issued photo ID or employer badge, verify date of birth, and record the verifier’s name. Accurate ID prevents mismatches and supports admissibility of results.

How is chain-of-custody documented?

Use sequential custody forms with signer initials, timestamps, specimen labels, and secure seals. Labs should assign accession numbers and record receipt to preserve evidentiary integrity.

Who may receive test results?

Results are released only to parties named in the agreement or permitted by law. In healthcare contexts HIPAA applies; covered entities require a BAA and must protect PHI accordingly.

What happens after a positive screen?

Positive screens typically trigger confirmatory testing and MRO review. Individuals should be notified per policy, given opportunity to explain prescriptions, and handled according to employer or clinical procedures.

Can the consent be revoked?

Consent can usually be withdrawn before collection; after a specimen is collected revocation may not undo testing already performed. Retention and reporting obligations may still apply under law or policy.

Electronic Signature
Templates
Miscellaneous
Drug Testing Urine Panel Agreement

Drug Testing Urine Panel Agreement

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

DRUG TESTING URINE PANEL AGREEMENT

RECITALS

WHEREAS, Client Name: (hereafter "Client") requires collection, laboratory analysis, and reporting of urine specimens for drug screening; and

WHEREAS, Service Provider Name: (hereafter "Provider") possesses the facilities, personnel, and laboratory relationships necessary to perform the requested urine drug panel testing in accordance with industry standards and applicable law; and

WHEREAS, the parties desire to set forth the terms, payment, confidentiality, and other conditions under which Provider will perform urine drug testing services for Client.

SCOPE OF WORK

Services to be Provided

Specimen Type: Collection Method:

Panel Selection

5-panel (Amphetamines, Cocaine, Marijuana, Opiates, Phencyclidine)
10-panel (includes additional prescription/illicit analytes)
Custom panel (specify):

CHAIN OF CUSTODY & COLLECTION

Collector / Facility Collection Location

Collection Date: Collection Time:

Chain-of-Custody Form Completed By:

PAYMENT TERMS

Fee Per Test: Estimated Number of Tests:

Payment Schedule

Late Payment Fee:

Invoicing Contact:

TERM AND TERMINATION

Agreement Effective Date: Agreement End Date (if any):

Termination for Convenience: Either party may terminate this Agreement upon written notice delivered at least days prior to the proposed termination date.

Termination for Cause: Either party may terminate immediately upon material breach by the other party if such breach is not cured within days after written notice of breach.

CONFIDENTIALITY

Provider and Client acknowledge that test results, chain-of-custody documentation, medical and personal identifying information, and billing information (collectively "Confidential Information") are sensitive. Provider shall maintain Confidential Information in strict confidence, shall limit access to personnel with a need to know, and shall not disclose Confidential Information except as required by law, court order, or with the express written consent of Client. Provider shall implement reasonable administrative, physical, and technical safeguards to protect Confidential Information.

Any permitted disclosure shall be limited to the minimum information necessary and Provider shall provide Client prompt written notice if a compelled disclosure is sought so Client may seek protective measures.

RESULTS RELEASE & AUTHORIZATION

I, the undersigned, authorize Provider to collect and test the specimen described above and to release results to the following authorized recipients:

Consent to Test: I consent to the collection and testing of my urine specimen and acknowledge the collection procedures and potential consequences of positive results as explained to me.

Additional Instructions / Restrictions

REPRESENTATIONS, WARRANTIES & INDEMNIFICATION

Provider represents that testing will be performed in accordance with accepted laboratory procedures and that staff are appropriately trained and certified where required. Client represents that specimens submitted are those of the identified donor and that Client is authorized to request testing and to receive results.

Each party shall indemnify and hold harmless the other from claims, liabilities, losses, and expenses (including reasonable attorneys' fees) arising from that party's negligence, willful misconduct, or breach of this Agreement.

GOVERNING LAW

This Agreement shall be governed by and construed in accordance with the laws of the State of , without regard to conflict of law principles.

ENTIRE AGREEMENT

This Agreement constitutes the entire agreement between the parties with respect to its subject matter and supersedes all prior or contemporaneous agreements, understandings, or representations, whether written or oral. Any amendment must be in writing and signed by both parties.

NOTICES

Notices required under this Agreement shall be in writing and delivered to the addresses below or to such other address as a party may designate in writing.

Client Notice Address Provider Notice Address

Client:

By:

Date:

Service Provider:

By:

Date:

What the Drug Testing Urine Panel Agreement Is

The Drug Testing Urine Panel Agreement is a written consent and authorization form used to document an individual's agreement to provide a urine specimen for drug screening, to set the scope of tests to be performed, and to record consent for release of results to designated parties. It typically specifies the testing panel, collection procedures, chain-of-custody controls, laboratory processing, and recipient entities such as employers or health providers. The agreement also outlines consequences of positive results, confidentiality limits, and any applicable pre-test disclosures required by law.

Why a Clear Agreement Matters

A clear Drug Testing Urine Panel Agreement reduces disputes by documenting consent, test scope, and result recipients, supports compliance with health and employment laws, and helps preserve chain-of-custody and privacy protections for sensitive health information.

Step-by-Step: Completing and Submitting the Agreement

Follow these steps to complete, collect, and submit the urine panel agreement while maintaining chain-of-custody and privacy protections.

01

Prepare Form: Complete all identifying fields and specify the test panel.
02

Verify Identity: Confirm government ID and record DOB and verifier name.
03

Collect Specimen: Follow observed collection procedures and label specimen immediately.
04

Send to Lab: Provide signed custody form and send specimen with secure transport.

Frequently Asked Questions

Answers to frequent questions about consent, specimen handling, e-signatures, privacy, and what to do after a positive result.

Need help? Contact support

Can the agreement be signed electronically?
Yes. Electronic signatures satisfy ESIGN (15 U.S.C. ch. 96) and UETA where adopted when intent, consent, attribution, and record retention are demonstrated. Exceptions such as wills or certain court filings remain excluded; follow consumer-consent requirements for healthcare-related records.
What identification is required at collection?
Collect a government-issued photo ID or employer badge, verify date of birth, and record the verifier’s name. Accurate ID prevents mismatches and supports admissibility of results.
How is chain-of-custody documented?
Use sequential custody forms with signer initials, timestamps, specimen labels, and secure seals. Labs should assign accession numbers and record receipt to preserve evidentiary integrity.
Who may receive test results?
Results are released only to parties named in the agreement or permitted by law. In healthcare contexts HIPAA applies; covered entities require a BAA and must protect PHI accordingly.
What happens after a positive screen?
Positive screens typically trigger confirmatory testing and MRO review. Individuals should be notified per policy, given opportunity to explain prescriptions, and handled according to employer or clinical procedures.
Can the consent be revoked?
Consent can usually be withdrawn before collection; after a specimen is collected revocation may not undo testing already performed. Retention and reporting obligations may still apply under law or policy.

Who Typically Completes This Agreement

Typical users include employers, occupational health clinicians, collection site personnel, and legal or HR staff responsible for compliance and recordkeeping.

Employer HR: requests testing, designates recipients, enforces policy and documents disciplinary steps.
Occupational Health Provider: verifies identity, explains consent, ensures medical confidentiality and proper specimen collection.
Laboratory/MRO: processes tests, issues confirmatory results, maintains chain-of-custody, and reports to designees.

Union representatives, legal counsel, and designated third parties may also engage, especially where collective bargaining or medical privacy issues arise.

Essential Information to Include

Signer Identity: Full legal name and DOB.

Specimen Details: Specimen ID and collection timestamp.

Selected Panel: List of analytes or panel type.

Collector Info: Collector name and signature.

Recipient List: Who may receive results.

Consent Statement: Signed authorization for testing.

Risks and Penalties for Errors

Privacy Violations: HIPAA or state penalties possible.

Chain-of-Custody Break: Tests may be inadmissible.

False Statements: Disciplinary or legal exposure.

Improper Consent: Results release may be unlawful.

Incorrect Reporting: Regulatory fines or disputes.

Missing Signatures: Invalid or delayed processing.

Common Preparation Mistakes to Avoid

Mismatched names or IDs between the form and photo identification cause delays, require re-verification, and can invalidate chain-of-custody records.
Incomplete collection logs or unlabeled specimens break evidentiary trails and may force labs to refuse testing or discard specimens.
Failing to list authorized result recipients or to obtain required healthcare consents can breach privacy laws and complicate result disclosure.
Using ambiguous panel descriptions or generic language invites disputes about which analytes were authorized and may trigger retesting demands.

How the Agreement Moves Through the Process

Overview of typical routing and processing steps after the agreement is completed and signed by all parties involved.

Collect: Collector verifies ID, labels specimen, completes custody log.
Test: Lab performs screening and confirmatory assays per panel.
Review: MRO reviews positives and medical explanations.
Report: Results released to authorized recipients listed in agreement.

Recommended Digital Workflow Settings

Suggested digital workflow settings for collecting and processing signed Drug Testing Urine Panel Agreements online.

Field	Configuration
Authentication	Email link or SMS code for signer verification
Required Fields	Name, DOB, collector initials, specimen ID
Audit Trail	Capture IP, timestamp, and action log
Storage Format	PDF/A with embedded audit certificate

Technical and Platform Considerations

Basic format, integration, and authentication features to support secure eSigning and recordkeeping.

Formats: PDF and DOCX supported
Integrations: EMR, HR, or LMS systems
Authentication: Email, SMS code, or KBA

Choose platforms that support secure storage, audit trails, and any required BAAs for healthcare; confirm export and archival formats meet regulatory needs.

Timelines and Processing Expectations

Key timing expectations for consent, specimen handling, confirmatory testing, and record retention to help set internal SLAs.

Consent Obtained:

Before specimen collection; must be documented.

Specimen Processing:

Labs typically process screening within 24–72 hours.

Confirmatory Testing:

Confirmatory assays usually complete within 48–72 hours after positive screen.

Report Delivery:

Delivery to designees follows MRO review and employer policy timelines.

Record Retention:

Retain according to retention schedule and applicable law.

eSignature Platform Pricing Snapshot

High-level price and capability comparison for common eSignature vendors when managing consent and authorization forms; signNow appears first as the first vendor column.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	Varies by plan	Varies by plan	Varies by plan	Varies by plan
Bulk Send	Yes (Premium tier)	Varies by plan	Varies by plan	Yes	Varies by plan
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes (BAA required)	Yes (BAA available)	Yes (BAA available)	No	No
Envelope Cap	No envelope cap	100 envelopes/user/year	Varies by plan	Varies by plan	Varies by plan

Practical Use Cases

Real-world examples showing how employers and clinics use the Drug Testing Urine Panel Agreement in common workflows.

Transportation Employer

A large fleet operator standardizes pre-employment and random testing forms to meet DOT and company policy.

Streamlined onboarding and testing chain-of-custody reduced administrative errors.
After implementing standardized forms and clear recipient lists, the company reported fewer verification delays and improved reproducibility of custody records during audits and investigations.

Community Health Clinic

A clinic uses the agreement for pre-treatment and return-to-work testing tied to care plans.

Ensures medical consent and HIPAA protections.
By specifying result recipients and obtaining explicit consent, the clinic reduced disclosure errors, improved patient trust, and kept consistent retention records for clinical audits.

Best Practices for Accurate, Efficient Completion

Practical recommendations to reduce errors, preserve evidence, and maintain privacy when using the Drug Testing Urine Panel Agreement.

Maintain Chain-of-Custody

Use sequential custody logs, specimen labels, and timestamped handoffs. Record collector and transport details to ensure admissibility and defensible results during audits or disputes.

Use Clear Consent Language

Spell out the test panel, result recipients, and consequences of positive results. Avoid vague terms and confirm that the signer understands privacy and disclosure provisions.

Protect Privacy and BAAs

When covered entities or PHI are involved, ensure a Business Associate Agreement (BAA) is in place with labs or eSignature vendors and limit disclosures to authorized recipients.

Standardize Retention and Access

Adopt a consistent retention schedule, secure storage, and role-based access controls. Document policies for retention, retrieval, and legal holds to avoid inadvertent deletion.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now